# OnCo record comfort-ii (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/comfort-ii/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "comfort-ii", "NCT00934544" ;
  schema:name "COMFORT-II"@en ;
  schema:alternateName "COMFORT"@en, "CINC424A2352"@en ;
  schema:description "COMFORT-II was the European companion to COMFORT-I: ruxolitinib shrank the spleen by more than a third in 28 percent of people with myelofibrosis after nearly a year, while not one patient on the best treatment their doctor could otherwise offer achieved that, and symptoms and quality of life improved."@en ;
  schema:url <https://onco.cc/trials/comfort-ii/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00934544> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/primary-myelofibrosis/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/ruxolitinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012/> .